Retour
Prokidney Corp (PROK) Gagner
Graphique du cours de l'action PROK
PROK Gagner
Prokidney Corp
$1.79
-7.73%
$-0.14
À la fermeture : Mar 24, 16:00:00 GMT-4
$1.81
1.67%
$0.02
Post-Marché: Mar 24, 20:00:00 GMT-4
Statistiques clés
Clôture préc.
$1.94
Prix d'ouverture
$1.91
Plage de la journée
$1.78 - $1.93
Plage de 52 semaines
$0.46 - $7.13
Volume
1.1M
Volume moyen
847.1K
Rendement en dividend
--
BPA (TTM)
-0.54
Capitalisation boursière
$547.4M
Qu’est-ce que PROK ?
ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The company is headquartered in Winston-Salem, North Carolina and currently employs 204 full-time employees. The company went IPO on 2021-06-30. The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.
Fonctionnalités
Ressources
© 2026 Finture Development Limited. Tous droits réservés.